However, GM-CSF has been controversial in treating ALS with mixed clinical findings showing that GM-CSF might not be important to ALS patients or at least not slow down the disease process (Mortada et al., 2021). The gene discussed is CSF2; the disease is amyotrophic lateral sclerosis.